Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Bonesso, Laurent ^a   Piraud, Monique ^d   Caruba, Céline ^a   Van Obberghen, Emmanuel ^a,b,c   Mengual, Raymond ^a   Hinault, Charlotte ^a,b,c  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^d Laboratory of Cardiogenetics   (France)

Author keywords

MALDI TOF TOF; Mass spectrometry; Oligosaccharidoses

Indexed keywords

FEMALE; HUMANS; LYSOSOMAL STORAGE DISEASES; MALE; OLIGOSACCHARIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84894228914     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-19     Document Type: Article

References (41)

1. Lysosomal metabolism of glycoproteins. Winchester B, Glycobiology 2005 15 1R 15R 15647514 (Pubitemid 41214369)
2. Lysosomal disorders. Wraith JE, Semin Neonatol 2002 7 75 83 10.1053/siny.2001.0088 12069540 (Pubitemid 34742221)
3. Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides. Ramsay SL, Meikle PJ, Hopwood JJ, Clements PR, Anal Biochem 2005 345 30 46 10.1016/j.ab.2005.06.042 16111643 (Pubitemid 41558192)
4. Insights into the diagnosis and treatment of lysosomal storage diseases. Wenger DA, Coppola S, Liu SL, Arch Neurol 2003 60 322 328 10.1001/archneur.60.3. 322 12633142 (Pubitemid 36314356)
5. Newborn screening of lysosomal storage disorders. Marsden D, Levy H, Clin Chem 2010 56 1071 1079 10.1373/clinchem.2009.141622 20489136
6. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA, Platt FM, Blood 2001 97 327 329 10.1182/blood.V97.1.327 11133779 (Pubitemid 32061278)
7. Bone marrow transplantation in young aspartylglucosaminuria mice: improved clearance of lysosomal storage in brain by using wild type as compared to heterozygote donors. Laine M, Ahtiainen L, Rapola J, Richter J, Jalanko A, Bone Marrow Transplant 2004 34 1001 1003 10.1038/sj.bmt.1704665 15489878 (Pubitemid 39600120)
8. Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy. Kelo E, Dunder U, Mononen I, Glycobiology 2005 15 79 85 15342551 (Pubitemid 40202041)
9. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Blanz J, Stroobants S, Lullmann-Rauch R, Morelle W, Ludemann M, D'Hooge R, Reuterwall H, Michalski JC, Fogh J, Andersson C, Saftig P, Hum Mol Genet 2008 17 3437 3445 10.1093/hmg/ddn237 18713755
10. Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. Dunder U, Valtonen P, Kelo E, Mononen I, J Inherit Metab Dis 2010 33 611 617 10.1007/s10545-010-9158-7 20607610
11. Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Damme M, Stroobants S, Walkley SU, Lullmann-Rauch R, D'Hooge R, Fogh J, Saftig P, Lubke T, Blanz J, J Neuropathol Exp Neurol 2011 70 83 94 10.1097/NEN.0b013e31820428fa 21157375
12. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in beta-galactosidase deficiency. Higaki K, Li L, Bahrudin U, Okuzawa S, Takamuram A, Yamamoto K, Adachi K, Paraguison RC, Takai T, Ikehata H, et al. Hum Mutat 2011 32 843 852 10.1002/humu.21516 21520340
13. Lysosomal accumulation of Trk protein in brain of GM (1) -gangliosidosis mouse and its restoration by chemical chaperone. Takamura A, Higaki K, Ninomiya H, Takai T, Matsuda J, Iida M, Ohno K, Suzuki Y, Nanba E, J Neurochem 2011 118 399 406 10.1111/j.1471-4159.2011.07310.x 21574998
14. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Krivit W, Peters C, Shapiro EG, Curr Opin Neurol 1999 12 167 176 10.1097/00019052- 199904000-00007 10226749 (Pubitemid 29209802)
15. Bone marrow transplantation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients. Arvio M, Sauna-Aho O, Peippo M, J Pediatr 2001 138 288 290 10.1067/mpd.2001.110119 11174635 (Pubitemid 32156453)
16. Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors. Malm G, Mansson JE, Winiarski J, Mosskin M, Ringden O, Transplantation 2004 78 415 419 15316370 (Pubitemid 39095408)
17. Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation. Miano M, Lanino E, Gatti R, Morreale G, Fondelli P, Celle ME, Stroppiano M, Crescenzi F, Dini G, Bone Marrow Transplant 2001 27 747 751 10.1038/sj.bmt.1702994 11360116 (Pubitemid 32409451)
18. Long-term follow-up of metachronous marrow-kidney transplantation in severe type II sialidosis: what does success mean? Schiff M, Maire I, Bertrand Y, Cochat P, Guffon N, Nephrol Dial Transplant 2005 20 2563 2565 10.1093/ndt/gfi063 16091374 (Pubitemid 41548892)
19. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, Finnegan N, Glomstein A, Jacobsohn DA, Kuhl JS, et al. Bone Marrow Transplant 2012 47 352 359 10.1038/bmt.2011.99 21552297
20. Successful unrelated bone marrow transplantation in two siblings with alpha-mannosidosis. Yesilipek AM, Akcan M, Karasu G, Uygun V, Kupesiz A, Hazar V, Pediatr Transplant 2012 16 7 779 782 10.1111/j.1399-3046.2012.01763.x 22775975
21. Bone marrow transplantation correcting beta-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis. Shield JP, Stone J, Steward CG, J Inherit Metab Dis 2005 28 797 798 10.1007/s10545-005- 0089-7 16151914 (Pubitemid 41349270)
22. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G, J Inherit Metab Dis 2010 33 suppl 3 355 S361 20821051
23. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, Tropak MB, Mol Genet Metab 2011 102 6 12 10.1016/j.ymgme.2010.09.004 20926324
24. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. Aguilar-Moncayo M, Takai T, Higaki K, Mena-Barragan T, Hirano Y, Yura K, Li L, Yu Y, Ninomiya H, Garcia-Moreno MI, et al. Chem Commun (Camb) 2012 48 6514 6516 10.1039/c2cc32065g 22618082
25. Oligosaccharides in urine of patients with glycoprotein storage diseases. I. Rapid detection by thin-layer chromatography. Humbel R, Collart M, Clin Chim Acta 1975 60 143 145 10.1016/0009-8981(75)90119-9 1126036
26. High-performance liquid chromatography of urinary oligosaccharides in the diagnosis of glycoprotein degradation disorders. Hommes FA, Varghese M, Clin Chim Acta 1991 203 211 224 10.1016/0009-8981(91)90293-L 1777982
27. Diagnosis of lysosomal storage disorders: current techniques and future directions. Meikle PJ, Fietz MJ, Hopwood JJ, Expert Rev Mol Diagn 2004 4 677 691 10.1586/14737159.4.5.677 15347261 (Pubitemid 39220841)
28. HPLC analysis of oligosaccharides in urine from oligosaccharidosis patients. Peelen GO, de Jong JG, Wevers RA, Clin Chem 1994 40 914 921 8087986 (Pubitemid 24166310)
29. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Chace DH, Kalas TA, Clin Biochem 2005 38 296 309 10.1016/j.clinbiochem.2005.01.017 15766731 (Pubitemid 40342860)
30. A mass spectrometric strategy for profiling glycoproteinoses, Pompe disease, and sialic acid storage diseases. Faid V, Michalski JC, Morelle W, Proteomics Clin Appl 2008 2 528 542 10.1002/prca.200780097 21136856 (Pubitemid 351566261)
31. Mass spectrometry in the study of lysosomal storage disorders. Meikle PJ, Fuller M, Hopwood JJ, Cell Mol Biol (Noisy-le-grand) 2003 49 769 777
32. Towards a selected reaction monitoring mass spectrometry fingerprint approach for the screening of oligosaccharidoses. Sowell J, Wood T, Anal Chim Acta 2011 686 102 106 10.1016/j.aca.2010.11.047 21237314
33. New fragmentation mechanisms in matrix-assisted laser desorption/ionization time-of-flight/time-of-flight tandem mass spectrometry of carbohydrates. Spina E, Sturiale L, Romeo D, Impallomeni G, Garozzo D, Waidelich D, Glueckmann M, Rapid Commun Mass Spectrom 2004 18 392 398 10.1002/rcm.1350 14966845 (Pubitemid 38235172)
34. Analysis of neutral oligosaccharides by matrix-assisted laser desorption/ionization mass spectrometry. Stahl B, Steup M, Karas M, Hillenkamp F, Anal Chem 1991 63 1463 1466 10.1021/ac00014a022
35. Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Papac DI, Wong A, Jones AJ, Anal Chem 1996 68 3215 3223 10.1021/ac960324z 8797382
36. Matrix optimization for matrix-assisted laser desorption/ionization mass spectrometry of oligosaccharides from human milk. Pfenninger A, Karas M, Finke B, Stahl B, Sawatzki G, J Mass Spectrom 1999 34 98 104 10.1002/(SICI)1096- 9888(199902)34:2<98::AID-JMS767>3.0.CO;2-N 10093211
37. Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update covering the period 1999-2000. Harvey DJ, Mass Spectrom Rev 2006 25 595 662 10.1002/mas.20080 16642463 (Pubitemid 44018026)
38. Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Fragaki K, Ait-El-Mkadem S, Chaussenot A, Gire C, Mengual R, Bonesso L, Beneteau M, Ricci JE, Desquiret-Dumas V, Procaccio V, et al. Eur J Hum Genet 2012 21 5 528 534 22990144
39. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Domon B, Costello CE, Glycoconj J 1988 5 397 409 10.1007/BF01049915 (Pubitemid 19031141)
40. Postsource decay fragmentation of N-linked carbohydrates from ovalbumin and related glycoproteins. Harvey DJ, J Am Soc Mass Spectrom 2000 11 572 577 10.1016/S1044-0305(00)00121-5 10833031 (Pubitemid 34521244)
41. Oligosaccharide analysis in urine by MALDI-TOF mass spectrometry for the diagnosis of lysosomal storage diseases. Xia B, Asif G, Arthur L, Pervaiz MA, Li X, Liu R, Cummings RD, He M, Clin Chem 2013 59 9 1357 1368 10.1373/clinchem. 2012.201053 23676310